HOME > COMMENTARY
COMMENTARY
-
Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
-
COMENTARY:Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
-
COMMENTARY/NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
-
COMMENTARY/Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
-
COMMENTARY/Market for Osteoporosis Drugs Booms
July 9, 2007
-
COMMENTARY/Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
-
COMMENTARY:Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply
June 25, 2007
-
COMMENTARY/Provisional Deliveries without Agreement on Prices
June 11, 2007
-
COMMENTARY/Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
-
COMMENTARY/Korosho to Consider Introduction of CU System
May 28, 2007
-
Explosion of Shin-Etsu Chemical's Cellulose Production PlantGood Opportunity to Reconsider Raw Material Procurement System
April 30, 2007
-
COMMENTARY/Japan Moves toward Affiliation with PIC/S
April 23, 2007
-
COMMENTARY/India Attracts Increasing Attention of Japanese Pharmas
April 16, 2007
-
COMMENTARY:Growing Market for Biopharmaceuticals
April 2, 2007
-
Japanese Pharma Companies' Licensing Policy: 1 (2) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
-
Comentary
March 26, 2007
-
Japanese Pharma Companies' Licensing Policy: 1 (1) Takeda Pharmaceutical Co., Ltd.
March 26, 2007
-
Future of the Life Sciences Industries: Strategies for Success in 2015
March 19, 2007
-
3 Advantages of Gov't-Private Sector Dialogue Industry Needs to Continuously Present Proposals
February 19, 2007
-
Breakthrough Pipelines of Japanese Pharma Companies Keiji Nakamura, Ph. D. Pharma Forum Institute, Kamakura 248-0026
February 12, 2007
ページ
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…